13.32
price down icon5.36%   -0.755
after-market Handel nachbörslich: 12.25 -1.07 -8.03%
loading
Schlusskurs vom Vortag:
$14.07
Offen:
$12.815
24-Stunden-Volumen:
23.80M
Relative Volume:
3.40
Marktkapitalisierung:
$1.31B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-248.39M
KGV:
-4.9517
EPS:
-2.69
Netto-Cashflow:
$-697.55M
1W Leistung:
-30.73%
1M Leistung:
-33.67%
6M Leistung:
-88.59%
1J Leistung:
-90.85%
1-Tages-Spanne:
Value
$12.60
$13.95
1-Wochen-Bereich:
Value
$12.60
$22.86
52-Wochen-Spanne:
Value
$12.60
$150.48

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name
Firmenname
Sarepta Therapeutics Inc
Name
Telefon
617-274-4000
Name
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Name
Mitarbeiter
1,372
Name
Twitter
@sarepta
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
SRPT's Discussions on Twitter

Vergleichen Sie SRPT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SRPT
Sarepta Therapeutics Inc
13.32 1.89B 2.23B -248.39M -697.55M -2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-18 Herabstufung Needham Buy → Hold
2025-06-20 Herabstufung William Blair Outperform → Mkt Perform
2025-06-18 Herabstufung TD Cowen Buy → Hold
2025-06-17 Eingeleitet Wolfe Research Peer Perform
2025-06-16 Herabstufung BMO Capital Markets Outperform → Market Perform
2025-06-16 Herabstufung BofA Securities Buy → Neutral
2025-06-16 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-06-16 Herabstufung H.C. Wainwright Neutral → Sell
2025-06-16 Herabstufung Morgan Stanley Overweight → Equal-Weight
2025-06-16 Herabstufung Piper Sandler Overweight → Neutral
2025-06-06 Hochstufung Scotiabank Sector Perform → Sector Outperform
2025-05-08 Herabstufung Evercore ISI Outperform → In-line
2025-04-11 Eingeleitet Wells Fargo Overweight
2025-04-02 Hochstufung H.C. Wainwright Sell → Neutral
2025-03-31 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2025-02-11 Eingeleitet Deutsche Bank Hold
2024-11-27 Bestätigt Needham Buy
2024-11-25 Eingeleitet H.C. Wainwright Sell
2024-11-07 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-10-21 Eingeleitet Jefferies Buy
2024-10-10 Fortgesetzt Raymond James Outperform
2024-07-29 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-06-26 Herabstufung Citigroup Buy → Neutral
2024-05-31 Eingeleitet Piper Sandler Overweight
2024-05-28 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2024-05-14 Hochstufung Oppenheimer Perform → Outperform
2024-01-31 Eingeleitet BMO Capital Markets Outperform
2023-12-13 Fortgesetzt Citigroup Buy
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-11-21 Eingeleitet Wedbush Outperform
2023-10-31 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-10-31 Herabstufung Oppenheimer Outperform → Perform
2023-06-23 Herabstufung Evercore ISI Outperform → In-line
2023-04-26 Eingeleitet SMBC Nikko Outperform
2023-04-04 Eingeleitet Citigroup Buy
2023-03-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-12-22 Bestätigt BTIG Research Buy
2022-12-16 Hochstufung UBS Neutral → Buy
2022-04-04 Fortgesetzt Cantor Fitzgerald Overweight
2022-01-05 Bestätigt Needham Buy
2021-12-09 Hochstufung Oppenheimer Perform → Outperform
2021-11-05 Hochstufung JP Morgan Neutral → Overweight
2021-09-15 Hochstufung Guggenheim Neutral → Buy
2021-08-05 Hochstufung JP Morgan Underweight → Neutral
2021-06-15 Eingeleitet BTIG Research Buy
2021-04-26 Fortgesetzt Credit Suisse Neutral
2021-01-12 Herabstufung Citigroup Buy → Neutral
2021-01-11 Herabstufung UBS Buy → Neutral
2021-01-08 Herabstufung JP Morgan Overweight → Underweight
2021-01-08 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-01-08 Herabstufung Raymond James Outperform → Mkt Perform
2020-11-11 Eingeleitet Berenberg Hold
2020-10-28 Eingeleitet UBS Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-08-20 Herabstufung Credit Suisse Outperform → Neutral
2020-03-31 Eingeleitet Mizuho Buy
2019-11-01 Eingeleitet Guggenheim Buy
2019-08-21 Bestätigt Needham Buy
2019-07-09 Bestätigt Morgan Stanley Overweight
2019-07-01 Bestätigt RBC Capital Mkts Outperform
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-03-11 Bestätigt Credit Suisse Outperform
2018-10-12 Eingeleitet Bernstein Outperform
2018-10-01 Eingeleitet Cantor Fitzgerald Overweight
2018-09-26 Bestätigt RBC Capital Mkts Outperform
2018-09-14 Fortgesetzt BofA/Merrill Buy
2018-09-06 Eingeleitet Credit Suisse Outperform
2018-08-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2018-06-21 Bestätigt Robert W. Baird Outperform
2018-06-20 Bestätigt Needham Buy
2018-06-19 Bestätigt H.C. Wainwright Buy
Alle ansehen

Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten

pulisher
05:50 AM

Sarepta’s Elevidys Halted at Children’s Hospital Los Angeles - Bloomberg

05:50 AM
pulisher
05:15 AM

Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths - The New York Times

05:15 AM
pulisher
04:20 AM

Sarepta under pressure: FDA requests halt of Elevidys shipments - Yahoo Finance

04:20 AM
pulisher
04:13 AM

Sarepta Worth $0 Amid ‘Unwinnable’ FDA Fight, HC Wainwright Says - Bloomberg

04:13 AM
pulisher
04:08 AM

Sarepta Dives, Again, As Its 'Unprecedented Times' Continue - Investor's Business Daily

04:08 AM
pulisher
03:37 AM

Sarepta Therapeutics laying off dozens in Ohio, won't comply with FDA request to halt therapy - The Columbus Dispatch

03:37 AM
pulisher
03:06 AM

Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets - Benzinga

03:06 AM
pulisher
02:24 AM

The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear - statnews.com

02:24 AM
pulisher
01:59 AM

Sarepta shares cut to $0 at H.C. Wainwright (SRPT:NASDAQ) - Seeking Alpha

01:59 AM
pulisher
12:58 PM

Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths - MedPage Today

12:58 PM
pulisher
12:43 PM

Navigating the Crossroads of Innovation and Safety: Assessing Sarepta Therapeutics in the Gene Therapy Landscape - AInvest

12:43 PM
pulisher
12:11 PM

Sarepta refuses to pull gene therapy despite FDA order - Yahoo Finance

12:11 PM
pulisher
11:58 AM

Arrowhead hits the skids due to partnership with Sarepta - Seeking Alpha

11:58 AM
pulisher
11:36 AM

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy - Fierce Biotech

11:36 AM
pulisher
11:16 AM

SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program - Yahoo Finance

11:16 AM
pulisher
10:42 AM

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market - Fierce Pharma

10:42 AM
pulisher
10:42 AM

Sarepta Stock Is Falling. How Its Crisis Went From Bad to Worse. - Barron's

10:42 AM
pulisher
10:35 AM

Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug - Investopedia

10:35 AM
pulisher
10:15 AM

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire

10:15 AM
pulisher
10:10 AM

Piper Sandler lowers Sarepta Therapeutics stock price target on Elevidys concerns - Investing.com

10:10 AM
pulisher
09:47 AM

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug - Yahoo Finance

09:47 AM
pulisher
09:32 AM

Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - TradingView

09:32 AM
pulisher
08:57 AM

Sarepta Therapeutics: Why Is SRPT Stock Crashing? - Forbes

08:57 AM
pulisher
08:45 AM

Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your RightsSRPT - Morningstar

08:45 AM
pulisher
08:32 AM

Sarepta Faces FDA Hold on Gene Therapy Trials - TipRanks

08:32 AM
pulisher
07:54 AM

Sarepta Stands Ground Against HHS Request To Stop Elevidys Shipments - BioSpace

07:54 AM
pulisher
07:54 AM

Sarepta slides as FDA places clinical hold on gene therapy clinical trials (SRPT:NASDAQ) - Seeking Alpha

07:54 AM
pulisher
07:53 AM

Sarepta Therapeutics stock rating reiterated at Hold by TD Cowen - Investing.com

07:53 AM
pulisher
07:45 AM

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys - Yahoo Finance

07:45 AM
pulisher
07:36 AM

SRPT DEADLINE REMINDER: Sarepta Therapeutics, Inc. Investors with Losses are Reminded to Contact BFA Law by the Upcoming August 25 Securities Fraud Deadline - Newsfile

07:36 AM
pulisher
07:33 AM

Sarepta Therapeutics stock price target slashed to $0 by H.C. Wainwright - Investing.com

07:33 AM
pulisher
06:57 AM

TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT) - StreetInsider

06:57 AM
pulisher
06:12 AM

Sarepta extends losses premarket after refusing FDA’s halt request (SRPT:NASDAQ) - Seeking Alpha

06:12 AM
pulisher
06:04 AM

BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT) - StreetInsider

06:04 AM
pulisher
02:44 AM

Sarepta Therapeutics (NASDAQ:SRPT) Cut to “Hold” at Needham & Company LLC - Defense World

02:44 AM
pulisher
02:43 AM

Oppenheimer Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $41.00 - Defense World

02:43 AM
pulisher
02:43 AM

Bank of America Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $20.00 - Defense World

02:43 AM
pulisher
01:22 AM

Leerink Partnrs Has Pessimistic Outlook of SRPT Q2 Earnings - Defense World

01:22 AM
pulisher
12:17 PM

What drives Sarepta Therapeutics Inc. stock priceExceptional earning trajectories - PrintWeekIndia

12:17 PM
pulisher
Jul 20, 2025

Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Sarepta Therapeutics Inc. stockFree Stock Selection - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 20, 2025
pulisher
Jul 20, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

SRPT SECURITIES NEWS: Did Sarepta Therapeutics, Inc. - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Q1 Earnings Estimate for SRPT Issued By Leerink Partnrs - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

Sarepta Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News

Jul 20, 2025
pulisher
Jul 20, 2025

Sarepta Therapeutics’ (SRPT) Hold Rating Reiterated at Needham & Company LLC - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies - Genetic Engineering and Biotechnology News

Jul 20, 2025
pulisher
Jul 19, 2025

This Gene Therapy Maker Refuses to Halt Shipments After Patient Deaths - Men's Journal

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline - Hoodline

Jul 19, 2025

Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
Kapitalisierung:     |  Volumen (24h):